MLKL and Alzheimer disease: Although no direct evidence currently supports RIPK1, RIPK3, or MLKL as predictors of β-amyloid plaque burden, Cst7—a disease-associated microglial (DAM) marker—has been shown to exhibit spatial proximity to β-amyloid plaques in both AD mouse models and postmortem human AD brain samples (Zhao et al., 2022).